231 related articles for article (PubMed ID: 15200432)
1. Up-regulation of hepatic Acyl CoA: Diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome.
Vaziri ND; Kim CH; Phan D; Kim S; Liang K
Kidney Int; 2004 Jul; 66(1):262-7. PubMed ID: 15200432
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of hepatic acyl-CoA:diglycerol acyltransferase in chronic renal failure.
Vaziri ND; Kim CH; Dang B; Zhan CD; Liang K
Am J Physiol Renal Physiol; 2004 Jul; 287(1):F90-4. PubMed ID: 15010358
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of hepatic LDL receptor-related protein in nephrotic syndrome: response to statin therapy.
Kim S; Kim CH; Vaziri ND
Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E813-7. PubMed ID: 15585592
[TBL] [Abstract][Full Text] [Related]
4. Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome.
Vaziri ND; Liang K
Am J Nephrol; 2004; 24(6):606-13. PubMed ID: 15583480
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome.
Vaziri ND; Liang K
Kidney Int; 2002 May; 61(5):1769-75. PubMed ID: 11967026
[TBL] [Abstract][Full Text] [Related]
6. Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome.
Vaziri ND; Liang KH
Circulation; 2004 Jul; 110(4):419-25. PubMed ID: 15262831
[TBL] [Abstract][Full Text] [Related]
7. Hepatic tissue sterol regulatory element binding protein 2 and low-density lipoprotein receptor in nephrotic syndrome.
Kim CH; Kim HJ; Mitsuhashi M; Vaziri ND
Metabolism; 2007 Oct; 56(10):1377-82. PubMed ID: 17884448
[TBL] [Abstract][Full Text] [Related]
8. Acyl-coenzyme A: cholesterol- acyl-coenzyme A:1,2-diacylglycerol acyltransferase and phosphatidate phosphorylase activities in liver microsomes from nephrotic rats.
Agbedana EO; Yamamoto T; Moriwaki Y; Takahashi S; Suda M; Higashino K
Afr J Med Med Sci; 1996 Dec; 25(4):365-71. PubMed ID: 9532309
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis.
Vaziri ND; Sato T; Liang K
Kidney Int; 2003 May; 63(5):1756-63. PubMed ID: 12675851
[TBL] [Abstract][Full Text] [Related]
10. Nephrotic syndrome causes upregulation of HDL endocytic receptor and PDZK-1-dependent downregulation of HDL docking receptor.
Vaziri ND; Gollapudi P; Han S; Farahmand G; Yuan J; Rahimi A; Moradi H
Nephrol Dial Transplant; 2011 Oct; 26(10):3118-23. PubMed ID: 21459782
[TBL] [Abstract][Full Text] [Related]
11. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
Yu XX; Murray SF; Pandey SK; Booten SL; Bao D; Song XZ; Kelly S; Chen S; McKay R; Monia BP; Bhanot S
Hepatology; 2005 Aug; 42(2):362-71. PubMed ID: 16001399
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of fenofibrate or simvastatin treatment of rats on hepatic microsomal overt and latent diacylglycerol acyltransferase activities.
Waterman IJ; Zammit VA
Diabetes; 2002 Jun; 51(6):1708-13. PubMed ID: 12031956
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of hepatic lipase expression in experimental nephrotic syndrome.
Liang K; Vaziri ND
Kidney Int; 1997 Jun; 51(6):1933-7. PubMed ID: 9186885
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice.
Liu Y; Millar JS; Cromley DA; Graham M; Crooke R; Billheimer JT; Rader DJ
Biochim Biophys Acta; 2008 Mar; 1781(3):97-104. PubMed ID: 18252207
[TBL] [Abstract][Full Text] [Related]
15. On the interrelationship between hepatic carnitine, fatty acid oxidation, and triglyceride biosynthesis in nephrosis.
al-Shurbaji A; Berglund L; Berge RK; Cederblad G; Humble E
Lipids; 1997 Aug; 32(8):847-52. PubMed ID: 9270976
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis.
Sato T; Liang K; Vaziri ND
Kidney Int; 2002 Jan; 61(1):157-62. PubMed ID: 11786096
[TBL] [Abstract][Full Text] [Related]
17. Astragalus mongholicus and Angelica sinensis compound alleviates nephrotic hyperlipidemia in rats.
Li J; Yu L; Li N; Wang H
Chin Med J (Engl); 2000 Apr; 113(4):310-4. PubMed ID: 11775225
[TBL] [Abstract][Full Text] [Related]
18. Hyperlipoproteinemia of aminonucleoside-induced nephrotic syndrome--modulation by glucocorticoids and triiodothyronine.
Shafrir E
Isr J Med Sci; 1996 Jun; 32(6):390-7. PubMed ID: 8682644
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of hepatic high-density lipoprotein receptor, SR-B1, in nephrotic syndrome.
Liang K; Vaziri ND
Kidney Int; 1999 Aug; 56(2):621-6. PubMed ID: 10432401
[TBL] [Abstract][Full Text] [Related]
20. Increased diacylglycerol acyltransferase activity is associated with triglyceride accumulation in tissues of diet-induced insulin-resistant hyperlipidemic hamsters.
Casaschi A; Maiyoh GK; Adeli K; Theriault AG
Metabolism; 2005 Mar; 54(3):403-9. PubMed ID: 15736121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
